Table 2.
Stage 1: development of brief FHQ–12: performance of each item to detect increased risk of marker condition
| Question numbera | Increased risk | |||||||
|---|---|---|---|---|---|---|---|---|
| Diabetes | Ischaemic heart disease | Breast cancer | Colorectal cancer | |||||
| Sensitivity, % (n) | Specificity, % (n) | Sensitivity, % (n) | Specificity, % (n) | Sensitivity, % (n) | Specificity, % (n) | Sensitivity, % (n) | Specificity, % (n) | |
| 1 | 80 (91/114) | 34 (168/491) | 81 (64/79) | 33 (177/535) | 88 (23/26) | 27 (103/382) | 77 (10/13) | 31 (189/601) |
| 2 | 37 (42/113) | 72 (354/494) | 92 (74/80) | 79 (425/536) | 35 (9/26) | 70 (267/384) | 15 (2/13) | 70 (420/603) |
| 3 | 98 (112/114) | 94 (461/493) | 36 (29/80) | 77 (412/536) | 23 (6/26) | 74 (286/384) | 38 (5/13) | 75 (455/603) |
| 5 | 4 (4/113) | 97 (473/490) | 4 (3/80) | 97 (514/532) | 4 (1/25) | 97 (372/384) | 0 (0/13) | 96 (578/599) |
| 6 | 5 (6/113) | 96 (474/494) | 6 (5/80) | 96 (515/536) | 28 (7/25) | 97 (374/385) | 0 (0/13) | 96 (577/603) |
| 7 | 10 (11/114) | 93 (461/494) | 8 (6/80) | 93 (498/537) | 50 (13/26) | 95 (367/385) | 8 (1/13) | 93 (560/604) |
| 8 | 18 (20/113) | 85 (417/493) | 24 (19/78) | 85 (456/537) | 73 (19/26) | 84 (321/384) | 15 (2/13) | 84 (504/602) |
| 10 | 6 (7/113) | 94 (460/491) | 5 (4/76) | 93 (502/537) | 7 (2/26) | 95 (363/382) | 85 (11/13) | 96 (573/600) |
| 11 | 16 (18/113) | 89 (439/492) | 16 (12/77) | 89 (477/537) | 12 (3/26) | 88 (338/384) | 54 (7/13) | 89 (535/601) |
| 12a | 73 (82/113) | 31 (150/491) | 67 (53/79) | 30 (158/533) | 100 (26/26) | 31 (120/382) | 77 (10/13) | 30 (181/599) |
| 12b | 31 (33/107) | 72 (334/467) | 31 (23/74) | 72 (364/509) | 58 (14/24) | 73 (267/366) | 25 (3/12) | 71 (406/571) |
a
Questions 4a, 4b, 9a, and 9b are not reported as the numbers were small.